Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059327 · ClinicalTrials.gov registry record · Phase 2
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
A Phase 2 study, sponsored by Noema Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT05059327 is a Phase 2 study that has completed, run by Noema Pharma. The registered enrollment target is 61 participants.
The verdict
NCT05059327, a Phase 2 study, has completed, sponsored by Noema Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
Interventions
- DRUG Basimglurant with crossover to Placebo
- DRUG Placebo with crossover to Basimglurant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2022-03-03 |
| Est. Completion | 2025-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05059327
The ClinicalTrials.gov registry entry for NCT05059327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noema Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Basimglurant with crossover to Placebo is the first listed.
NCT05059327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05059327 about?
NCT05059327 is a clinical study titled "Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC". The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
What is the current status of trial NCT05059327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2022-03-03. Estimated completion is 2025-04-28.
What interventions are being tested in trial NCT05059327?
The interventions under investigation include: Basimglurant with crossover to Placebo (DRUG), Placebo with crossover to Basimglurant (DRUG).
Who is sponsoring clinical trial NCT05059327?
This trial is sponsored by Noema Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.